Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL (CLASSIFY)

2. listopadu 2026 aktualizováno: Hellenic Institute for the Study of Sepsis

The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized with community-acquired pneumonia (CAP), sepsis, and sepsis-induced immunoparalysis (SII). The primary objective is to evaluate the effect of clarithromycin on the incidence of new infection, including worsening or recurrence of the initial CAP episode, new infections at other sites, and secondary sepsis during the 28-day follow-up period. Secondary objectives are to investigate the impact of clarithromycin on mortality, sepsis response, type of secondary infection, time to antimicrobial escalation, hospital readmission, quality of life, cost-effectiveness, and biomarkers of sepsis-induced immunoparalysis.

Researchers will compare clarithromycin plus standard-of-care antibiotic therapy to placebo plus standard-of-care antibiotic therapy.

Participants will:

  • Receive clarithromycin or placebo, administered orally or intravenously, in addition to standard-of-care antibiotic therapy for up to 7 days.
  • Be evaluated during treatment and follow-up through Day 28, with additional assessment of mortality, hospital readmission, and health status through Day 90.

Přehled studie

Postavení

Nábor

Podmínky

Intervence / Léčba

Detailní popis

Pneumonia remains the leading cause of sepsis-related deaths worldwide and is one of the primary causes for antimicrobial resistance development. Despite advances in antimicrobial therapy and supportive care, community-acquired pneumonia (CAP) frequently progresses into sepsis and septic shock, resulting in high mortality and prolonged hospitalization.

Sepsis is a heterogeneous syndrome, and patients may present different patterns of immune dysfunction. Sepsis-induced immunoparalysis (SII) is characterized by profound downregulation of both innate and adaptive immune responses, with features including decreased monocyte human leukocyte antigen-DR (HLA-DR) expression, lymphopenia, and impaired production of interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α). Patients with SII are at increased risk of secondary infections and late mortality.

There is currently no universally accepted bedside method for identifying SII. Most publications suggest one of the following: exhaustion of peripheral blood mononuclear cells (PBMCs) for the ex vivo production of TNFα, absolute number of HLA-DR receptors on CD14-monocytes less than 8,000/cell, and blood levels of IFNγ less than 3pg/ml. These methods may be complex and are not widely available in routine clinical practice. Absolute lymphocyte count (ALC) has therefore been proposed as a readily available bedside marker of immune dysfunction. Previous analyses have shown an association between low ALC and SII and adverse outcomes. In particular, an ALC below 800/mm³ has demonstrated high specificity for SII, while an ALC below 1,000/mm³ has been associated with increased mortality in hospitalized patients. Other studies have suggested different thresholds, reflecting the lack of an established diagnostic cutoff for SII.

Clarithromycin is a macrolide antibiotic with established antimicrobial activity and additional immunomodulatory properties. Previous randomized controlled trials in patients with sepsis have shown that adjunctive clarithromycin may improve laboratory markers of immune dysfunction. These effects have included increased cytokine production by PBMCs and increased expression of HLA-DR on circulating monocytes, consistent with partial reversal of SII. In the randomized controlled trials INCLASS and ACCESS, adjunctive clarithromycin was also associated with a reduction in secondary infections among sepsis survivors. However, SII was not used as an inclusion criterion in these previous studies, and improvement in clinical outcomes was not the primary objective. These findings provide a rationale for evaluating clarithromycin specifically in patients with sepsis and evidence of SII.

The CLASSIFY trial is designed to determine whether adjunctive treatment with clarithromycin, administered IV or orally, can reduce the incidence of new infection episodes, including secondary sepsis, within 28 days in patients with CAP-RELATED sepsis, and evidence of SII. By focusing on an immunologically defined population, this study aims to validate the immunomodulatory benefit of clarithromycin, clarify its role as an adjunctive therapy for reversing SII, and contribute to precision immunotherapy strategies in sepsis management. The CLASSIFY trial is distinguished by the fact that it introduces the ALC as a beside tool to identify SII and for sensitivity analyses allowing validation of the ALC for diagnosis of SII.

The primary objective of the CLASSIFY trial is to determine whether clarithromycin added to standard-of-care antibiotic therapy reduces the 28-day incidence of new infections compared with placebo plus standard-of-care antibiotic therapy in patients with CAP-related sepsis and SII. The primary outcome is a composite endpoint including worsening or recurrence of the initial CAP episode, development of a new infection at a non-pulmonary site, and secondary sepsis.

Secondary objectives are to evaluate the effect of clarithromycin on 28-day and 90-day survival, duration of hospitalization, improvement in organ dysfunction after seven days, the relationship between changes in ALC and the development of specific secondary infections, restoration of immunological function, and the cost-effectiveness of treatment. The study will also evaluate biomarkers associated with SII, including IFN-γ, HLA-DR expression, TNF-α production following ex vivo stimulation, serum lipids, ferritin, soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), soluble TNF receptor-1 (sTNFR-1), interleukin-6 (IL-6), interleukin-8 (IL-8), protein C, and plasminogen activator inhibitor-1 (PAI-1).

CLASSIFY is a prospective, multicenter, double-blind, randomized, placebo-controlled Phase III clinical trial that will be conducted at 19 investigator sites in Greece.

Adult patients of either sex hospitalized with CAP and sepsis will be screened for eligibility. CAP will be defined by the presence of a new consolidation on chest imaging in a patient with a compatible clinical presentation, such as fever, dyspnea, cough, or sputum production, without a history of contact with a hospital or healthcare facility for two or more days during the preceding 90 days. Sepsis will be defined according to the Sepsis-3 classification criteria as an increase of at least 2 points in the total Sequential Organ Failure Assessment (SOFA-1) score compared with the patient's baseline score. The CLASSIFY protocol uses SOFA-1 for the definition of sepsis; data required for both SOFA-1 and SOFA-2 will be collected during the study.

Eligible participants must have an ALC below 1,000/mm³. The baseline ALC will be determined from a complete blood count obtained within 48 hours before enrolment. Investigators will make every reasonable effort to determine the patient's pre-existing baseline SOFA-1 score using available medical records and relevant clinical information.

Patients will be excluded if they are younger than 18 years, do not provide informed consent, are pregnant or lactating, or are unwilling to use highly effective contraception during treatment and for seven days following administration of the investigational medicinal product when applicable. Other exclusion criteria include known HIV infection with a CD4 count of 200/mm³ or less, solid-organ or bone marrow transplantation, significant recent immunosuppressive treatment, recent biological therapy, active malignancy or another condition associated with an expected survival of less than six months, severe neutropenia, treatment with a macrolide for the CAP episode under study, significant QT prolongation or known long QT syndrome, history of macrolide allergy or torsades de pointes, and concomitant use of medications contraindicated with clarithromycin. Patients with severe hypokalemia or hypomagnesemia may become eligible after correction of the electrolyte abnormality. Patients with severe hepatic failure combined with renal impairment, contraindications to macrolide treatment, previous participation in CLASSIFY, or participation in another interventional clinical trial within the preceding 30 days will also be excluded. Finally, patients receiving oral or intravenous corticosteroids greater than 0.4 mg/kg of equivalent prednisone daily over the last 15 days, or other immunosuppressive therapy. However, corticosteroids received as adjunctive treatment for the current septic/ infectious episode are allowed.

Following informed consent and confirmation of eligibility, patients will be randomized in a 1:1 ratio to receive either standard-of-care antibiotic therapy plus clarithromycin or standard-of-care antibiotic therapy plus placebo.

Typ studie

Intervenční

Zápis (Odhadovaný)

252

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Evangelos J Giamarellos-Bourboulis, Professor
  • Telefonní číslo: 0030 2105831994
  • E-mail: egiamarel@med.uoa.gr

Studijní místa

  • Řecko
    • Achaea
      • Pátrai, Achaea, Řecko, 265 04
        • Nábor
        • General University Hospital of Patras, Department of Internal Medicine
        • Kontakt:
          • Karolina Akinosoglou, Professor
          • Telefonní číslo: +306977762897
          • E-mail: akin@upatras.gr
        • Vrchní vyšetřovatel:
          • Karolina Anthoula Akinosoglou, Professor
    • Attica
      • Athens, Attica, Řecko, 106 76
        • Nábor
        • Evaggelismos Hospital, 1st Department of Internal Medicine
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Theano Kontopoulou
      • Athens, Attica, Řecko, 115 26
        • Nábor
        • General Hospital of Athens Korgialenio Benakio H.R.C, Intensive Care Unit
        • Vrchní vyšetřovatel:
          • Maria Patrani
        • Kontakt:
      • Athens, Attica, Řecko, 115 26
        • Nábor
        • General Hospital of Athens Korgialenio Benakio H.R.C., 1st Department of Internal Medicine
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Vasiliki Tzavara
      • Athens, Attica, Řecko, 115 27
        • Nábor
        • General Hospital of Athens G.Gennimatas, 1st Department of Internal Medicine
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Georgios Adamis
      • Athens, Attica, Řecko, 115 27
        • Nábor
        • Thoracic General Hospital of Athens I Sotiria, 3rd University Department of Internal Medicine
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Garyfallia Poulakou, Associate Professor
      • Athens, Attica, Řecko, 115 27
        • Nábor
        • Thoracic General Hospital of Athens I Sotiria, 6th Department of Pulmonary Medicine
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Ioannis A Ioannis
      • Athens, Attica, Řecko, 115 28
        • Nábor
        • General Hospital of Athens Alexandra, Ηigh Dependency Unit of Department of Clinical Therapeutics
        • Kontakt:
          • Georgios Dimopoulos, Professor
          • Telefonní číslo: +306944756565
          • E-mail: gdimop@med.uoa.gr
        • Vrchní vyšetřovatel:
          • Georgios Dimopoulos, Professor
      • Athens, Attica, Řecko, 124 61
        • Nábor
        • University General Hospital Attikon-General Hospital of West Attica H Agia Varvara, 2nd Department of Propaedeutic Medicine
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Eleni Boutati, Professor
      • Athens, Attica, Řecko, 124 61
        • Nábor
        • University General Hospital Attikon-General Hospital of West Attica H Agia Varvara, 4th Department of Internal Medicine
        • Kontakt:
          • Evangelos J. Giamarellos Bourboulis
          • Telefonní číslo: +306945521800
          • E-mail: egiamarel@med.uoa.gr
        • Vrchní vyšetřovatel:
          • Antonios Papadopoulos, Professor
      • Athens, Attica, Řecko, 145 64
        • Nábor
        • General Oncological Hospital of Kifisia Agioi Anargyroi, Intensive Care Unit
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Pavlos Myrianthefs, Professor
    • Ioannina
      • Ioannina, Ioannina, Řecko, 455 00
        • Nábor
        • University General Hospital of Ioannina, 1st Department of Internal Medicine
        • Kontakt:
          • Charalampos Milionis, Professor
          • Telefonní číslo: +30 6944521512
          • E-mail: hmilioni@uoi.gr
        • Vrchní vyšetřovatel:
          • Charalampos Milionis, Professor
    • Thessaloniki
      • Thessaloniki, Thessaloniki, Řecko, 546 36
        • Nábor
        • University General Hospital of Thessaloniki Ahepa, Intensive Care Unit
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Eleni Argyriadou, Professor
      • Thessaloniki, Thessaloniki, Řecko, 546 42
        • Nábor
        • Ippokratio General Hospital of Thessaloniki, 2nd Propaedeutic Department of Internal Medicine
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Michael Doumas, Professor
      • Thessaloniki, Thessaloniki, Řecko, 564 29
        • Nábor
        • General Hospital of Thessaloniki Papageorgiou, Department of Internal Medicine
        • Kontakt:
          • Vasileios Kotsis, Professor
          • Telefonní číslo: 6974748860
          • E-mail: vkotsis@auth.gr
        • Vrchní vyšetřovatel:
          • Vasileios Kotsis, Professor
      • Thessaloniki, Thessaloniki, Řecko, 570 10
        • Nábor
        • Geniko Nosokomeio Thessalonikis George Papanikolaou, Intensive Care Unit
        • Vrchní vyšetřovatel:
          • Athina Lavrentieva
        • Kontakt:
    • Thrace
      • Alexandroupoli, Thrace, Řecko, 681 00
        • Nábor
        • University General Hospital of Alexandroupolis, 2nd Department of Internal Medicine
        • Kontakt:
          • Periklis Panagopoulos, Professor
          • Telefonní číslo: +30 6944410495
          • E-mail: ppanago@med.duth.gr
        • Vrchní vyšetřovatel:
          • Periklis Panagopoulos, Professor
    • West Attica
      • Elefsina, West Attica, Řecko, 190 18
        • Nábor
        • General Hospital of Eleusina Thriasio, 1st Department of Internal Medicine
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Styliani Sympardi, MD
      • Elefsina, West Attica, Řecko, 190 18
        • Nábor
        • General Hospital of Eleusina Thriasio, 2nd Department of Internal Medicine
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Konstantina Iliopoulou, MD

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Age equal to or above 18 years
  • Patients of either gender
  • Written informed consent provided by the patient. For patients without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation.
  • Negative (blood or urinary) pregnancy test for female patients of reproductive age
  • For female patients of reproductive age, willingness to use highly effective contraception during and seven days after the administration of the IMP.
  • Presence of Community-acquired pneumonia (CAP)
  • Presence of sepsis as defined by the Sepsis-3 classification criteria (at least 2 points increase of the total SOFA-1 score from the baseline score of the specific patient). The SOFA score which will be used for the definition of sepsis has recently been renamed SOFA-1.
  • Absolute lymphocyte count (ALC) less than 1000/mm³.

Exclusion Criteria:

  • Age below 18 years
  • Denial of written informed consent
  • Pregnancy (confirmed by blood or urinary pregnancy test) or lactation for female patients
  • Unwillingness to receive contraception during and seven days after the administration of the IMPstudy drug (for Female patients)
  • Known HIV infection with known CD4 cell count <200/mm³
  • Solid organ or bone marrow transplantation
  • Corticosteroid oral or intravenous intake greater than 0.4mg/kg of equivalent prednisone daily over the last 15 days or other immunosuppressive therapy. However, corticosteroids received as adjunctive treatment for the current septic/infectious episode are allowed
  • Intake of a biological agent in the last month
  • Known active neoplasms or other conditions unrelated to sepsis that compromise short-term survival less than 6 months
  • Neutropenia < 500/mm³
  • Intake of any macrolide for the current episode of CAP under study
  • QTc interval at rest in the ECG ≥500 msec or history of known long QT syndrome
  • Medical history of allergy to macrolides
  • Concomitant use of medicinal products contraindicated with clarithromycin, including CYP3A substrates associated with QT prolongation (e.g., astemizole, cisapride, domperidone, pimozide, terfenadine, ivabradine), ergot alkaloids (e.g., ergotamine, dihydroergotamine), oral midazolam, HMG-CoA reductase inhibitors primarily metabolised by CYP3A4 (e.g., lovastatin, simvastatin), colchicine, ticagrelor, and ranolazine. This criterion applies to all medicinal products within these classes, not only the specific examples listed, in accordance with the SmPC for clarithromycin. Patients may be enrolled provided that such medications are discontinued prior to or at the time of trial participation. Given their short half-life, no wash-out period is required
  • Medical history of torsades de pointes arrhythmia
  • Severe hypokalemia or hypomagnesemia; patients may be enrolled once these electrolyte abnormalities are corrected.
  • Any contradictions for macrolide uptake
  • Previous participation in the CLASSIFY study
  • Participation in any other interventional trial within the last 30 days
  • Severe hepatic failure in combination with renal impairment

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Komparátor placeba: Standard-of-care (SoC) and placebo

In the case of IV placebo medication, patients receive water for injection at a volume of 10ml diluted to a final volume of 250 ml dextrose in water 5%. The duration of the infusion is 1 hour and treatment is given every 12 hours daily for 7 days.

In the case of oral placebo medication, this is given as oral tablets every 12 hours once for 7 days.

Step-down from IV to oral medication, respectively, is permitted.
Lék: Placebo

There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.
Aktivní komparátor: Standard-of-care (SoC) and clarithromycin

In the case of IV medication, patients receive 500 mg of clarithromycin diluted with water for injection at a volume of 10ml and further diluted to a final volume of 250 ml dextrose in water 5%. The duration of the infusion is 1 hour and treatment is given every 12 hours daily for 7 days.

In the case of oral medication, this is given as clarithromycin IR 500mg every 12 hours for 7 days.

Step-down from IV to oral medication, respectively, is permitted.
Lék: clarithromycin

There is no other intervention in this clinical study and participation in another clinical study is an exclusion criterion.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Incidence of new infection
Časové okno: Day 1 through Day 28.

The incidence of new infection within 28 days following randomization, comparing intravenous or oral clarithromycin plus standard-of-care (SoC) antibiotic therapy with placebo plus SoC. The composite endpoint includes any of the following:

  • Worsening of the CAP episode, defined as the need to change SoC antibiotic treatment during the first 7 days. A change to moxifloxacin due to detection of atypical pathogens is not considered worsening.
  • Recurrence of CAP symptoms after initial improvement, requiring initiation of new treatment or a change in treatment after Day 7.
  • Any new infection at a non-pulmonary site during the first 28 days.
  • Secondary sepsis occurring between Day 8 and Day 28, defined as the onset of a new infection or recurrence of the CAP episode accompanied by an increase of at least 2 points in the total SOFA-1 score compared with the SOFA-1 score immediately before the new infection or CAP recurrence.
Day 1 through Day 28.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
All-cause mortality at Day 28
Časové okno: Day 28.

Proportion of participants who die from any cause within 28 days after randomization.
Day 28.
All-cause mortality at Day 90
Časové okno: Day 90.

Proportion of participants who die from any cause within 90 days after randomization.
Day 90.
Sepsis response at Day 7
Časové okno: Day 7.

Proportion of participants achieving at least a 25% decrease in the total SOFA-1 score from the pre-treatment Day 1 score by Day 7.
Day 7.
Type of new sepsis episode
Časové okno: Through Day 28.

Characterization of new sepsis episodes according to the predominant pathogen and site of infection.
Through Day 28.
Each of the elements of the composite primary endpoint separately
Časové okno: Through Day 28.

Incidence of each individual component of the primary composite endpoint, analyzed separately: worsening of the CAP episode, recurrence of CAP symptoms, new infection at a non-pulmonary site, and secondary sepsis.
Through Day 28.
Time to antimicrobial escalation
Časové okno: Through Day 28.

Time from randomization to escalation or change of antimicrobial treatment, measured in days.
Through Day 28.
Need for hospital readmission up to day 90
Časové okno: up to day 90 from enrollment

Proportion of participants requiring hospital readmission for any reason following hospital discharge after randomization up to day 90
up to day 90 from enrollment
Analysis (comparison) of all secondary endpoints for the subgroup of patients (number of patients, %) defined by each physiological parameter that was followed for randomization per investigator site.
Časové okno: According to the corresponding secondary endpoint.

Analysis of all secondary endpoints for the subgroups of patients (number of patients, %) defined by each treatment parameter that was followed for randomization per investigator site. The three parameters (treatment pathways) are:

  1. oral or iv administration of the investigational medical product (placebo or clarithromycin)
  2. treatment or not with intravenous corticosteroids (total daily dose of at least 200mg hydrocortisone or equivalent)
  3. Absolute lymphocyte count less than 800/mm³ or between 800 and 1000/mm³
According to the corresponding secondary endpoint.
Comparison of outcomes between patients who receive intravenous clarithromycin and patients who receive oral clarithromycin.
Časové okno: Through Day 90.

Comparison of clinical outcomes (primary and secondary endpoints) between participants receiving intravenous clarithromycin and participants receiving oral clarithromycin.
Through Day 90.
Patient status self-report documented by the EQ-5D questionnaire or a bespoke visual-analog scale.
Časové okno: During follow-up through Day 90.

Use of standardized questionnaires to measure health-related quality of life
During follow-up through Day 90.
Incremental cost-effectiveness ratio
Časové okno: From day 1 through day 90.

Incremental cost-effectiveness ratios (ICERs) comparing clarithromycin plus standard-of-care antibiotic therapy with placebo plus standard-of-care antibiotic therapy, cross-referenced with patient health status.
From day 1 through day 90.
Biomarkers of sepsis-induced immunoparalysis
Časové okno: Study days 1, 4 and 8

Serial assessment of biomarkers associated with sepsis-induced immunoparalysis/immunosuppression, including IFN-γ, absolute count of HLA-DR receptors on CD45/CD14-monocytes by flow cytometry. TNF-α production by ex vivo stimulation of peripheral blood monocytes (PBMCs), serum lipids, ferritin, sTREM-1, sTNFR-1, IL-6, IL-8, protein C, and PAI-1.
Study days 1, 4 and 8

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Sepsis response by SOFA-2
Časové okno: Day 7.

Proportion of participants achieving at least a 25% decrease in the total SOFA-2 score from the pre-treatment Day 1 score by Day 7.
Day 7.
Primary endpoint according to baseline IL-6 and IFN-γ levels
Časové okno: Through Day 28.

Analysis of the primary composite endpoint according to patient subgroups defined by baseline levels of IL-6 and IFN-γ.
Through Day 28.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Hellenic Institute for the Study of Sepsis

Vyšetřovatelé

  • Studijní židle: Evangelos J Giamarellos-Bourboulis, Professor, Hellenic Institute for the Study of Sepsis

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

16. září 2026

Primární dokončení (Odhadovaný)

1. října 2029

Dokončení studie (Odhadovaný)

1. prosince 2029

Termíny zápisu do studia

První předloženo

26. srpna 2026

První předloženo, které splnilo kritéria kontroly kvality

16. září 2026

První zveřejněno (Aktuální)

22. září 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

3. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. listopadu 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • CLASSIFY
  • 2025 (Grant/smlouva NIH USA)
  • 2025-525058-20-00 (Ctis)

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit